| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | BI-2536 | FIMM | pan-cancer | AAC | 0.021 | 0.9 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | -0.008 | 0.9 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |